Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study

• Status: Completed
• Trial end date: 2017-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Study objective: To investigate the potential therapeutic efficacy of enteric-coated mycophenolate sodium combined with low-dose corticosteroid as first-line treatment for minimal change nephrotic syndrome (MCNS).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Hong Kong
• Treatments: Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Mycophenolate mofetil; Mycophenolic Acid; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

• Male or female 18 - 65 years of age

• First histologic diagnosis of MCNS

• Proteinuria > 3.5 g/day

• Patients who are willing to give written, informed consent

Exclusion Criteria:

• Presence of secondary causes of MCNS

• History of glomerular disease including MCNS

• eGFR < 50 ml/min/1.73m2

• Renal histology showing pathologies other than MCNS

• Female of child-bearing age who are unwilling to practice effective contraception

• Patients simultaneously participating in another study or who have participated in another study within the last 30 days of entry into this study